- Endometrial cancer risk and survival by tumor MMR status
-
Nagle CM, O'Mara TA, Tan Y, Buchanan D, Obermair A, Blomfield , Quinn MA, Webb PM, Spurdle AB, on behalf of the Australian Endometrial Cancer Study Group
- KMID: 2409940
- J Gynecol Oncol.
- 2018 May;29(3):e39.
- doi: 10.3802/jgo.2018.29.e39
OBJECTIVE: The risk of developing endometrial cancer (EC) and/or survival following a diagnosis of EC might differ by tumor DNA mismatch repair (MMR) status. We assessed the association between tumor... -
- CITED
-
- Close
- SHARE
-
- Close
- Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
-
Blinman P, Gainford C, Donoghoe M, Martyn J, Blomfield , Grant P, Kichenadasse G, Vaughan M, Brand A, Shannon C, Gebski V, Stockler M, Friedlander M
- KMID: 2177878
- J Gynecol Oncol.
- 2013 Oct;24(4):359-366.
- doi: 10.3802/jgo.2013.24.4.359
OBJECTIVE: Intraperitoneal (IP) chemotherapy in women with optimally debulked stage III ovarian cancer has been reported to prolong overall survival, but has not been widely adopted due to concerns about... -
- CITED
-
- Close
- SHARE
-
- Close
